|
End-of-day quote
Korea S.E.
2026-09-14
|
5-day change | 1st Jan Change | ||
| 16,270.00 KRW | -3.56% |
|
-6.22% | -71.66% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-21 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 181M | - | - | - | - | - |
| 45.63B | |||||
| 43.96B | - | - | - | - | - |
| 43.73B | |||||
| 40.23B | |||||
| 31.86B |
- Stock Market
- Stocks
- A287840 Stock
- Charts IntoCell, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
